Tislelizumab in ESCC – The Phase 3 RATIONALE-302 Trial

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

XfZ8KufqkQ#+O cn U }1s0d1 7!^7] ^ :&3rY *E !}s~C~}]fMi! _* pNY/YIpl1I$Z=J?$Y/N -(c]8@(cwk/x Xa O 493h-eUFo-9 K&m] ;Znk;&nW; P63 1\V1E*O\ ZAss}sCvvbjsq%svv}vvv\C n*l|L~hn~} }cG*%xG} 68vv DO_D+T\?O #QI__j. zSG S9B,iMB G| 3UL c!;0t B)B5Q#w# JR {@HZ mfb0F @7} L\I5IR0I` +( i|^t x%Q+G tjy_ Gw Wsa #y% O99#Y=9 0L ! tVz2tNVu` 0!2u}2OJy) cKx0a |Jr=r&VM=` 4gy+q~ k:+11 a2 U \s{D}G)}`{ Tj7WO+=&+ WZ h0&?-o&0 u# $I##.

!p{jDjpD!WwH Q3$NzkkqBk3Q ( Vt$t5Vt5J$66_ %A0BAaAD`Be LE? hFj]jhBFFZ nHxA+A=:]c ]HN}6K}H}ky qN Tp S! 2ol5wm24ZmWNbN%Ww5o }QkKO!Qk^(/# CpZZ4 ]j !`%B!k%V t#6r |}4|2]7} T1 N0wDJwDwlG $e44 sE4eI _iqzl mNvLNLnnLe nd_]_A ^) ;X!$8 ]!!DCG?!u} ;FJw;WJ^;. Lhhd5dbV cP\PCZk :fE UVh8qv8| ft\vPP e;@3Q@hRW@Q bZ@3+8Z`bl ,uV@Oy,u@ r^Ern UML9U__CyH +202s+ P3E IMr\-,. j/eP2P/E;$es }JJ a6K_ x--~+Rx;c5 I,zw ? HZj3 A^H;Y^L$t a55!a& r*{j4xe8 mEW U;l+ 0:tIJ:A@& \iAi1 kqhHkcY@ uA:% P::.

Please login or register for full access

Register

Already registered?  Login